The Business Research Company’s report on the Idefirix Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the idefirix market in recent years?
The increasing prevalence and incidence of kidney diseases is expected to propel the growth of the idefirix market going forward. Kidney diseases are conditions that damage the kidneys’ function or structure, hindering their ability to filter waste and maintain fluid balance in the body. The increasing prevalence and incidence of kidney diseases can be attributed to factors such as an aging population, rising rates of diabetes and hypertension, lifestyle choices, and genetic predispositions. Idefirix, a groundbreaking immunoglobulin G (IgG)-degrading enzyme therapy, helps kidney disease patients by enabling highly sensitized individuals to undergo life-saving kidney transplants by effectively reducing donor-specific antibodies that would otherwise cause transplant rejection. For instance, in June 2023, according to a report published by the kidney research, a UK-based research organization, the incidence of acute kidney injury is projected to increase from an estimated 615,000 cases in 2022 to 637,000 by 2033. Therefore, increasing prevalence and incidence of kidney diseases is driving the growth of the idefirix market.
Access Your Free Sample of the Global Idefirix Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=20093&type=smp
What is the projected market size of the idefirix industry, and how is it expected to grow?
The idefirix market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased incidence of allergic diseases, increased doses of the drug, increased prevalence of chronic diseases, a rise in demand for organ transplants, and increased prevalence and incidence of kidney diseases.
The idefirix market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing kidney waiting list volumes, increasing awareness regarding organ donation, increasing research and development, rising number of procedures and FDA approvals, and rising awareness of antibody-mediated rejection. Major trends in the forecast period include advancements in antibody-cleaving enzyme technology, increasing investments in transplant immunology research, collaboration with transplant centers for clinical integration, a growing focus on personalized medicine, and government initiatives for organ transplantation.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=20093&type=smp
Who are the key players driving competition in the idefirix market?
Major companies operating in the idefirix market include Hansa Biopharma AB
What key trends are expected to drive the hyqvia market during the forecast period?
The key trend in the idefirix market is focusing on developing innovative solutions, such as desensitization treatment, to desensitize highly sensitized kidney transplant patients. Desensitization treatment is a medical procedure that removes or reduces harmful antibodies, enabling transplant patients to receive organs from incompatible donors. For instance, in July 2023, Hansa Biopharma, a Sweden-based biopharmaceutical company, announced that the Australian Therapeutic Goods Administration (TGA), an Australia-based regulatory authority, approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients. This approval enables these patients to receive kidney transplants from both living and deceased donors. The treatment works by reducing or removing harmful anti-donor antibodies, which can otherwise prevent transplantation. Based on positive results from Hansa Biopharma’s phase 2 studies, this approval marks a significant step in improving kidney transplant options for highly sensitized patients in Australia.
Which key geographies are driving the growth of the idefirix market?
Europe was the largest region in the idefirix market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/idefirix-global-market-report
What are the key segments driving growth in the idefirix market?
The idefirix market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Kidney Transplantation, Desensitization Protocols
3) By End-User: Hospitals, Specialized Clinics, Home Healthcare
4) By Distribution Channel: Direct Sales, Pharmacies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20093
What defines the structure and scope of the idefirix market?
Idefirix (imlifidase) is an enzyme-based medication designed to reduce donor-specific antibodies in highly sensitized kidney transplant patients, enabling successful organ transplantation. It is used to desensitize patients awaiting kidney transplants by cleaving IgG antibodies, increasing compatibility with available donors.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
